Stock Groups

Lilly to supply up to 220,000 COVID-19 antibody combo doses to European countries By Reuters


© Reuters. FILEPHOTO: FILEPHOTO: A pharmaceutical manufacturing facility owned by Eli Lilly and Company is shown at 50 ImClone Drive, Branchburg, New Jersey on March 5, 2021. REUTERS/Mike Segar

(Reuters) -Eli Lilly on Tuesday announced a pact with the European Commission to supply up to 220,000 doses of its COVID-19 dual antibody cocktail to European countries for patients aged 12 years and older who are at a high risk of progressing to severe disease.

Bamlanivimab plus etesevimab are the two main treatments. They can be used in patients without COVID-19.

Following authorization by Lilly, countries within the European Union/European Economic Area will be able to buy the products directly from Lilly. Lilly also said that quantities may differ depending on the local need.

Lilly explained that while many European countries previously placed orders for bamlanivimab, etesevimab, in the first six months of the year, they have sufficient inventory to go around, the new agreement gives them access to more doses, should any need arise.

According to the drugmaker, there is no impact expected on its financial outlook for 2021 from this agreement.

Lilly announced last week that 388,000 more doses of COVID-19, the drugmaker’s COVID-19-based antibody therapy, were purchased by the U.S. Government. This will allow it to pair with its existing supply of bamlanivimab.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.